KPV dosage chart

Reconstitution steps

1. 1Draw 1mL of bacteriostatic water into a sterile syringe.
2. 2Inject the water slowly down the inside wall of the 10MG KPV vial.
3. 3Swirl gently until fully dissolved — do not shake.
4. 4Use a U-100 insulin syringe for accurate dosing.
5. 5Store reconstituted solution refrigerated at 2–8 °C, protected from light.

Spartan Peptides official protocol

Example: 5 units = 500mcg KPV (0.5mg). Adjust based on individual response and goals. Consistent daily use is commonly researched for best results. Inject subcutaneously.

• Mixing guide: mix 10MG KPV with 1mL BAC water.
• Concentration after mixing: 10 mg/mL (1 unit = 0.1mg).
• Recommended dosage: 250mcg – 1mg daily.
• Injection frequency: Daily — 1–2 times daily.
• Use an insulin syringe (U-100) for accurate dosing.

Reported research focus

Research purposes only. Premium quality. Built on legacy. Backed by science.

• Supports gut health*
• Supports skin health*
• Reduces inflammation*
• Supports recovery*

Important Notes

Practical considerations for consistency and safety.

• Use new sterile insulin syringes for each administration; dispose in a sharps container immediately after use.
• Rotate injection sites systematically (abdomen, thighs, upper arms) at least 1–2 inches apart to reduce local irritation and prevent lipohypertrophy.
• Inject slowly; wait a few seconds before withdrawing the needle to prevent solution backflow.
• Document daily dose, injection site, and any observations to maintain consistency and track tolerability.
• If injection‑site reactions (redness, mild swelling) occur, apply a cool compress and monitor; persistent reactions warrant protocol review.

How This Works

KPV is the C‑terminal tripeptide sequence (residues 11–13) of α‑melanocyte‑stimulating hormone (α‑MSH), retaining potent anti‑inflammatory activity without the hormone’s melanotropic effects. Preclinical studies demonstrate KPV reduces pro‑inflammatory cytokines (TNF‑α, IL‑6, IL‑1β) and modulates immune cell activity in models of inflammatory bowel disease, colitis, and systemic inflammation. The peptide’s mechanism involves inhibition of nuclear factor kappa B (NF‑κB) signaling and modulation of inflammatory mediator release. Subcutaneous administration provides systemic delivery with rapid absorption and sustained anti‑inflammatory effects observed in daily dosing protocols.

Potential Benefits & Side Effects

Observations from preclinical and early‑stage research.

• Anti‑inflammatory activity: Reduces pro‑inflammatory cytokines and modulates immune responses in models of inflammatory bowel disease and systemic inflammation.
• Oral and subcutaneous efficacy: Multiple routes of administration show activity, with subcutaneous injection favored for systemic delivery and consistent bioavailability.
• Wound healing support: Preclinical data suggest KPV may support tissue repair and wound healing processes through inflammatory modulation.
• Generally well tolerated: Occasional mild injection‑site reactions (redness, slight swelling) may occur; systemic side effects are rarely reported in research protocols.
• No melanotropic effects: Unlike full α‑MSH, KPV does not affect melanocyte activity or skin pigmentation.

Lifestyle Factors

Complementary strategies for optimizing inflammatory balance.

• Anti‑inflammatory diet: Emphasize whole foods, omega‑3 fatty acids, polyphenols, and minimize processed foods and refined sugars.
• Stress management: Chronic stress elevates inflammatory markers; incorporate stress‑reduction practices (meditation, yoga, adequate sleep).
• Physical activity: Regular moderate exercise supports healthy inflammatory balance; avoid overtraining which can increase inflammation.
• Sleep optimization: Prioritize 7–9 hours of quality sleep nightly to support immune regulation and inflammatory homeostasis.
• Gut health: Support microbiome diversity through probiotic‑rich foods and adequate fiber intake, particularly relevant for inflammatory bowel conditions.

Injection Technique

General subcutaneous guidance from clinical best‑practice resources.

• Clean the vial stopper and injection site with alcohol swabs; allow to dry completely (10–15 seconds).
• Pinch a 1–2 inch skinfold; insert the needle at 45–90° angle into subcutaneous tissue.
• Do not aspirate for subcutaneous injections; inject slowly and steadily over 3–5 seconds.
• Withdraw the needle smoothly and apply gentle pressure with a clean alcohol swab (do not rub the site).
• Rotate sites systematically using a pattern (e.g., alternating between right/left abdomen, right/left thigh) to avoid lipohypertrophy and maintain consistent absorption.
• Preferred sites: abdomen (at least 2 inches from navel), anterior/lateral thigh, or outer upper arm (if administering to self, abdomen and thigh are easiest).

important-note

This content is intended for therapeutic educational purposes only and does not constitute medical advice, diagnosis, or treatment. KPV is a research peptide not approved by regulatory agencies for human therapeutic use. Consult qualified healthcare professionals before beginning any peptide protocol. This information is provided for educational and research reference purposes only.

KPV dosage FAQs